Dear Editor, KIT (also known as c-KIT) is a receptor tyrosine kinase expressed on various cell types [1] . KIT mutations are detected in approximately 5% of patients newly diagnosed with acute myeloid leukemia (AML) and in 20-30% of patients with core-binding factor AML [2, 3] . KIT mutations are predominantly presented as one or two amino acid substitutions affecting codon 816. The most frequent mutation type, D816V, is detected in about 40% of cases with AML, where KIT is mutated [4] . In AML with t(8;21), the presence of KIT mutation at codon 816 is associated with a high white blood cell (WBC) count at diagnosis, a high incidence of extramedullary leukemia, and high risk of relapse during the course of the disease [5] . Other less frequent types of KIT mutation are D816Y, D816H, and D816I. KIT mutations present a prognostic significance. The National Comprehensive Cancer Network categorized AML with either t(8;21) or inv(16)/t(16;16) combined with KIT mutations as the intermediate-risk group [6]. We report a novel INDEL mutation in KIT codon 816, discovered in a woman with AML with t(8;21) (q22;q22); RUNX1-RUNX1T1.
PolyPhen-2 score is the probability of the substitution being damaging; ‡ SABLE Protein structure: H (helix), E (beta strand), C (coil); § SABLE Relative solvent accessibility: level of exposure (0-completely buried, 9-fully exposed); || SABLE Physicochemical properties: H-hydrophobic, N-negatively charged.
http://sift.jcvi.org/; J. Craig Venter Institute, La Jolla, CA, USA) [7] , exploiting the degree of conservation of amino acid residues derived from functionally related protein sequences, D816L, I817L, and D816V mutations were predicted to be 'damaging', with a SIFT score equal to 0 (the amino acid substitution is predicted as 'damaging' if the score is ≤ 0.05). Using PolyPhen-2 (Polymorphism Phenotyping v2, version 2.2.2, http://genetics.bwh. harvard.edu/pph2/; Division of Genetics, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA) [8] to predict the possible impact of an amino acid substitution on the structure and function of a protein using several features, including sequences, phylogenetic, and structural information, D816L and I817L were predicted to be 'probably damaging' with a score of 1.000, and 'possibly damaging' with a score of 0.955, respectively. By comparison, the D816V mutation was predicted to be 'probably damaging', with a score of 0.999. Using SABLE (Accurate prediction of Solvent AccessiBiLitiEs, version 2, http://sable. cchmc.org/; Division of Biomedical Informatics, Children's Hospital Research Foundation, Cincinnati, OH, USA) [9] , which predicts the relative solvent accessibility of amino acid residues and secondary structures in proteins using evolutionary profiles, the D816_I817delinsLL mutation was predicted to present physicochemical properties similar to those of D816V when compared with both the wild-type and the D816V mutation (Fig. 1D) . In the physicochemical property prediction, both D816V and D816_I817delinsLL were predicted to be hydrophobic, whereas the wild type D816 and I817 were predicted to be negatively charged and hydrophobic, respectively. Considering these insilico prediction results, we concluded that the clinical significance of D816_I817delinsLL mutation would be similar to that of the pathogenic D816V mutation.
In the follow-up BM examination, one month after the induction chemotherapy using idarubicin and cytarabine, the BM aspirate smear showed 14% of myeloblasts and the response was determined as resistant disease [10] . In the next follow-up BM examination, one month after re-induction chemotherapy using daunorubicin and cytarabine, 3% of myeloblasts were observed on the BM aspirate smear, and the patient was diagnosed with a morphological leukemia-free state. This is the first report on a novel KIT INDEL mutation in exon 17, D816_I817delinsLL.
